Loading…
Gujarat Kidney and Super Speciality (GKSL)₹154.87−2.66%Hospital
In the Jun 2026 quarter (consolidated), Gujarat Kidney and Super Speciality reported sales of ₹34.17 Cr, up 124.5% from Jun 2025, and net profit of ₹5.34 Cr, down 1.5% year on year. For the year to Mar 2026, sales were ₹81.83 Cr and net profit ₹17.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 9.39 | 11.76 | 9.75 | 15.22 | 12.90 | 23.19 | 30.52 | 34.17 |
| Expenses | 4.57 | 7.21 | 7.19 | 6.66 | 7.84 | 16.42 | 24.36 | 26.00 |
| Operating Profit | 4.84 | 4.58 | 2.60 | 8.59 | 5.10 | 6.88 | 6.28 | 8.33 |
| OPM % | 51.7% | 39.1% | 26.8% | 56.5% | 39.6% | 29.7% | 20.7% | 24.5% |
| Other Income | 0.03 | 0.04 | 0.04 | 0.00 | 0.08 | 0.05 | 0.70 | 0.68 |
| Interest | 0.17 | 0.18 | 0.17 | 0.19 | 0.29 | 0.61 | 0.83 | 0.67 |
| Depreciation | 0.75 | 0.89 | 0.91 | 0.97 | 0.91 | 1.34 | 1.52 | 1.45 |
| Profit before tax | 4.01 | 3.61 | 1.61 | 7.52 | 4.04 | 5.05 | 4.69 | 6.97 |
| Tax % | 26.2% | 29.7% | 16.9% | 27.8% | 28.6% | 26.4% | −3.0% | 23.6% |
| Net Profit | 2.97 | 2.54 | 1.35 | 5.42 | 2.89 | 3.71 | 4.84 | 5.34 |
| EPS (Rs) | 18.40 | 15.52 | 0.24 | 0.86 | 0.46 | 0.38 | 0.65 | 0.67 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 0.00 | 4.98 | 39.90 | 81.83 | 101 |
| Expenses | 0.00 | 3.01 | 24.08 | 55.19 | 74.62 |
| Operating Profit | 0.00 | 1.99 | 16.94 | 26.90 | 26.59 |
| OPM % | — | 41.0% | 41.1% | 33.1% | 26.4% |
| Other Income | 0.00 | 0.99 | 0.00 | 0.99 | 1.51 |
| Interest | 0.00 | 0.00 | 1.01 | 2.01 | 2.40 |
| Depreciation | 0.00 | 0.00 | 3.01 | 5.02 | 5.22 |
| Profit before tax | 0.00 | 2.01 | 13.05 | 21.04 | 20.75 |
| Tax % | 0.0% | 25.0% | 26.0% | 21.0% | — |
| Exceptional items | 0.00 | 1.01 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 2.01 | 10.04 | 17.05 | 16.78 |
| EPS (Rs) | −0.49 | 85.53 | 1.67 | 1.98 | 2.16 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.21 | 0.21 | 11.04 | 16.06 |
| Reserves | 0.00 | 10.97 | 14.95 | 237 |
| Borrowings | 0.00 | 5.99 | 7.97 | 28.94 |
| Other Liabilities | 3.98 | 4.02 | 21.05 | 16.08 |
| Total Liabilities | 3.99 | 20.99 | 55.01 | 298 |
| Fixed Assets | 0.00 | 14.01 | 31.05 | 129 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 3.99 | 6.98 | 23.96 | 169 |
| Inventories | 0.00 | 0.00 | 0.99 | 1.99 |
| Trade receivables | 1.01 | 4.01 | 15.03 | 39.08 |
| Cash & equivalents | 0.00 | 0.99 | 2.99 | 55.93 |
| Total Assets | 3.99 | 20.99 | 55.01 | 298 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | 1.01 | 14.02 | −4.01 |
| Cash from investing activity | 0.00 | −17.99 | −214 |
| Cash from financing activity | 0.00 | 6.02 | 229 |
| Net cash flow | 0.99 | 1.99 | 10.99 |
| Capex | 0.00 | 18.01 | 11.01 |
| Free cash flow | 1.99 | −4.99 | −14.98 |
| CFO / OP % | 70.0% | 99.0% | −14.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 321 | 138 | 172 |
| Inventory days | — | — | 81 |
| Days payable | — | — | 340 |
| Cash conversion cycle | 321 | 138 | −84 |
| Working capital days | 100 | −24 | 91 |
| ROCE % | 19.0% | 52.0% | 14.0% |
For the Jun 2026 quarter, Gujarat Kidney and Super Speciality reported sales of ₹34.17 Cr, up 124.5% year on year and net profit of ₹5.34 Cr, down 1.5% year on year. The operating margin was 24.5%.
Gujarat Kidney and Super Speciality's sales for the year to Mar 2026 were ₹81.83 Cr; over the last twelve months they were ₹101 Cr.
Net profit for the year to Mar 2026 was ₹17.05 Cr, and ₹16.78 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.16.
Gujarat Kidney and Super Speciality reported borrowings of ₹28.94 Cr at Mar 2026, against cash and equivalents of ₹55.93 Cr.
Cash from operations was −₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹14.98 Cr.